<p>Kaplan-Meier graph illustrating cardiovascular mortality in the study population in NYHA functional class I, in those supplemented with selenium and coenzyme Q10 versus placebo during four years on top of regular pharmaceutic treatment during a follow-up period of 10 years.</p
<p>Kaplan-Meier curves, adjusted for competing risks, showing cumulative cardiovascular morbidity an...
<p>Note: ACEI: ACE- inhibitors; ARB; Angiotension receptor blockers; EF: Ejection fraction; IHD; Isc...
<p>Distribution of cardiovascular mortality in placebo and active treatment groups above and below m...
<p>Kaplan-Meier graph illustrating cardiovascular mortality in the study population in NYHA function...
<p>Kaplan-Meier graph illustrating cardiovascular mortality in the study population in NYHA function...
<p>Kaplan-Meier graph illustrating cardiovascular mortality in the study population in those supplem...
<p>Kaplan-Meier graph illustrating cardiovascular mortality in the study population with ischemic he...
<p>Kaplan-Meier graph illustrating cardiovascular mortality during a follow-up period of 12 years of...
<p>Kaplan-Meier graph illustrating cardiovascular mortality in participants with ischemic heart dise...
<p>Kaplan-Meier graph illustrating cardiovascular mortality in participants with hypertension during...
<p>Kaplan-Meier graph illustrating cardiovascular mortality in participants with diabetes during a f...
<p>Censored: patients who were still alive at the end of the follow-up period, or who died from non-...
<p>Distribution of cardiovascular mortality among those with a C-reactive protein concentration belo...
<p>Notes: EF: Ejection fraction; IHD: Ischemic heart disease; NT-proBNP: N-terminal fragment of proB...
<p>Notes: EF: Ejection fraction; IHD: Ischemic heart disease; NT-proBNP: N-terminal fragment of proB...
<p>Kaplan-Meier curves, adjusted for competing risks, showing cumulative cardiovascular morbidity an...
<p>Note: ACEI: ACE- inhibitors; ARB; Angiotension receptor blockers; EF: Ejection fraction; IHD; Isc...
<p>Distribution of cardiovascular mortality in placebo and active treatment groups above and below m...
<p>Kaplan-Meier graph illustrating cardiovascular mortality in the study population in NYHA function...
<p>Kaplan-Meier graph illustrating cardiovascular mortality in the study population in NYHA function...
<p>Kaplan-Meier graph illustrating cardiovascular mortality in the study population in those supplem...
<p>Kaplan-Meier graph illustrating cardiovascular mortality in the study population with ischemic he...
<p>Kaplan-Meier graph illustrating cardiovascular mortality during a follow-up period of 12 years of...
<p>Kaplan-Meier graph illustrating cardiovascular mortality in participants with ischemic heart dise...
<p>Kaplan-Meier graph illustrating cardiovascular mortality in participants with hypertension during...
<p>Kaplan-Meier graph illustrating cardiovascular mortality in participants with diabetes during a f...
<p>Censored: patients who were still alive at the end of the follow-up period, or who died from non-...
<p>Distribution of cardiovascular mortality among those with a C-reactive protein concentration belo...
<p>Notes: EF: Ejection fraction; IHD: Ischemic heart disease; NT-proBNP: N-terminal fragment of proB...
<p>Notes: EF: Ejection fraction; IHD: Ischemic heart disease; NT-proBNP: N-terminal fragment of proB...
<p>Kaplan-Meier curves, adjusted for competing risks, showing cumulative cardiovascular morbidity an...
<p>Note: ACEI: ACE- inhibitors; ARB; Angiotension receptor blockers; EF: Ejection fraction; IHD; Isc...
<p>Distribution of cardiovascular mortality in placebo and active treatment groups above and below m...